Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

Diederik Decock; P Verschueren; D De Cock; L Corluy; R Joos; C Langenaken; V Taelman; F Raeman; I Ravelingien; K Vandevyvere; J Lenaerts; E Geens; P Geusens; J Vanhoof; A Durnez; J Remans; B Vander Cruyssen; E Van Essche; A Sileghem; G De Brabanter; J Joly; K Van der Elst; S Meyfroidt; R Westhovens; CareRA study group

doi:10.1186/s13075-015-0611-8

Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

Diederik Decock, P Verschueren, D De Cock, L Corluy, R Joos, C Langenaken, V Taelman, F Raeman, I Ravelingien, K Vandevyvere, J Lenaerts, E Geens, P Geusens, J Vanhoof, A Durnez, J Remans, B Vander Cruyssen, E Van Essche, A Sileghem, G De BrabanterJ Joly, K Van der Elst, S Meyfroidt, R Westhovens, CareRA study group

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION: Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down glucocorticoids in the CareRA trial. METHODS: Disease-modifying antirheumatic drug-naive patients with eRA were stratified into a low-risk group based on prognostic markers that included non-erosiveness, anti-citrullinated protein antibodies and rheumatoid factor negativity and low disease activity (Disease Activity Score in 28 joints based on C-reactive protein (DAS28(CRP))

Original language	English
Journal	Arthritis Res Ther
Volume	17
DOIs	https://doi.org/10.1186/s13075-015-0611-8
Publication status	Published - 2015

Keywords

Adult
Aged
Antirheumatic Agents/*therapeutic use
Area Under Curve
Arthritis, Rheumatoid/blood/*diagnosis/*drug therapy
Biomarkers/blood
C-Reactive Protein/*analysis
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Glucocorticoids/*therapeutic use
Humans
Male
Methotrexate/*therapeutic use
Middle Aged
Prognosis
Prospective Studies
Severity of Illness Index
Time Factors
Treatment Outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13075-015-0611-8

http://www.ncbi.nlm.nih.gov/pubmed/25889222

Fingerprint

Dive into the research topics of 'Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial'. Together they form a unique fingerprint.

Cite this

Decock, D., Verschueren, P., De Cock, D., Corluy, L., Joos, R., Langenaken, C., Taelman, V., Raeman, F., Ravelingien, I., Vandevyvere, K., Lenaerts, J., Geens, E., Geusens, P., Vanhoof, J., Durnez, A., Remans, J., Vander Cruyssen, B., Van Essche, E., Sileghem, A., ... CareRA study group (2015). Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther, 17. https://doi.org/10.1186/s13075-015-0611-8

@article{2271630578dc47efbde1f49d3e4968c4,

title = "Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial",

abstract = "INTRODUCTION: Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down glucocorticoids in the CareRA trial. METHODS: Disease-modifying antirheumatic drug-naive patients with eRA were stratified into a low-risk group based on prognostic markers that included non-erosiveness, anti-citrullinated protein antibodies and rheumatoid factor negativity and low disease activity (Disease Activity Score in 28 joints based on C-reactive protein (DAS28(CRP))",

keywords = "Adult, Aged, Antirheumatic Agents/*therapeutic use, Area Under Curve, Arthritis, Rheumatoid/blood/*diagnosis/*drug therapy, Biomarkers/blood, C-Reactive Protein/*analysis, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glucocorticoids/*therapeutic use, Humans, Male, Methotrexate/*therapeutic use, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome",

author = "Diederik Decock and P Verschueren and {De Cock}, D and L Corluy and R Joos and C Langenaken and V Taelman and F Raeman and I Ravelingien and K Vandevyvere and J Lenaerts and E Geens and P Geusens and J Vanhoof and A Durnez and J Remans and {Vander Cruyssen}, B and {Van Essche}, E and A Sileghem and {De Brabanter}, G and J Joly and {Van der Elst}, K and S Meyfroidt and R Westhovens and {CareRA study group}",

note = "Verschueren, Patrick De Cock, Diederik Corluy, Luk Joos, Rik Langenaken, Christine Taelman, Veerle Raeman, Frank Ravelingien, Isabelle Vandevyvere, Klaas Lenaerts, Jan Geens, Elke Geusens, Piet Vanhoof, Johan Durnez, Anne Remans, Jan Vander Cruyssen, Bert Van Essche, Els Sileghem, An De Brabanter, Griet Joly, Johan Van der Elst, Kristien Meyfroidt, Sabrina Westhovens, Rene England Arthritis Res Ther. 2015 Apr 9;17:97. doi: 10.1186/s13075-015-0611-8.",

year = "2015",

doi = "10.1186/s13075-015-0611-8",

language = "English",

volume = "17",

journal = "Arthritis Res Ther",

issn = "1478-6362",

publisher = "Springer Nature",

}

Decock, D, Verschueren, P, De Cock, D, Corluy, L, Joos, R, Langenaken, C, Taelman, V, Raeman, F, Ravelingien, I, Vandevyvere, K, Lenaerts, J, Geens, E, Geusens, P, Vanhoof, J, Durnez, A, Remans, J, Vander Cruyssen, B, Van Essche, E, Sileghem, A, De Brabanter, G, Joly, J, Van der Elst, K, Meyfroidt, S, Westhovens, R & CareRA study group 2015, 'Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial', Arthritis Res Ther, vol. 17. https://doi.org/10.1186/s13075-015-0611-8

Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. / Decock, Diederik; Verschueren, P; De Cock, D et al.
In: Arthritis Res Ther, Vol. 17, 2015.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

AU - Decock, Diederik

AU - Verschueren, P

AU - De Cock, D

AU - Corluy, L

AU - Joos, R

AU - Langenaken, C

AU - Taelman, V

AU - Raeman, F

AU - Ravelingien, I

AU - Vandevyvere, K

AU - Lenaerts, J

AU - Geens, E

AU - Geusens, P

AU - Vanhoof, J

AU - Durnez, A

AU - Remans, J

AU - Vander Cruyssen, B

AU - Van Essche, E

AU - Sileghem, A

AU - De Brabanter, G

AU - Joly, J

AU - Van der Elst, K

AU - Meyfroidt, S

AU - Westhovens, R

AU - CareRA study group

N1 - Verschueren, Patrick De Cock, Diederik Corluy, Luk Joos, Rik Langenaken, Christine Taelman, Veerle Raeman, Frank Ravelingien, Isabelle Vandevyvere, Klaas Lenaerts, Jan Geens, Elke Geusens, Piet Vanhoof, Johan Durnez, Anne Remans, Jan Vander Cruyssen, Bert Van Essche, Els Sileghem, An De Brabanter, Griet Joly, Johan Van der Elst, Kristien Meyfroidt, Sabrina Westhovens, Rene England Arthritis Res Ther. 2015 Apr 9;17:97. doi: 10.1186/s13075-015-0611-8.

PY - 2015

Y1 - 2015

N2 - INTRODUCTION: Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down glucocorticoids in the CareRA trial. METHODS: Disease-modifying antirheumatic drug-naive patients with eRA were stratified into a low-risk group based on prognostic markers that included non-erosiveness, anti-citrullinated protein antibodies and rheumatoid factor negativity and low disease activity (Disease Activity Score in 28 joints based on C-reactive protein (DAS28(CRP))

AB - INTRODUCTION: Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down glucocorticoids in the CareRA trial. METHODS: Disease-modifying antirheumatic drug-naive patients with eRA were stratified into a low-risk group based on prognostic markers that included non-erosiveness, anti-citrullinated protein antibodies and rheumatoid factor negativity and low disease activity (Disease Activity Score in 28 joints based on C-reactive protein (DAS28(CRP))

KW - Adult

KW - Aged

KW - Antirheumatic Agents/therapeutic use

KW - Area Under Curve

KW - Arthritis, Rheumatoid/blood/diagnosis/drug therapy

KW - Biomarkers/blood

KW - C-Reactive Protein/analysis

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Female

KW - Glucocorticoids/therapeutic use

KW - Humans

KW - Male

KW - Methotrexate/therapeutic use

KW - Middle Aged

KW - Prognosis

KW - Prospective Studies

KW - Severity of Illness Index

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1186/s13075-015-0611-8

DO - 10.1186/s13075-015-0611-8

M3 - Article

SN - 1478-6362

VL - 17

JO - Arthritis Res Ther

JF - Arthritis Res Ther

ER -